» Articles » PMID: 23049402

Recommended Screening and Preventive Practices for Long-term Survivors After Hematopoietic Cell Transplantation

Abstract

Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (e.g. umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, periand post-transplant exposures and risk-factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.

Citing Articles

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity.

Shaffer B, Brown S, Chinapen S, Mangold K, Lahoud O, Lopez-Jimenez F Blood Adv. 2024; 8(21):5603-5611.

PMID: 39158065 PMC: 11550362. DOI: 10.1182/bloodadvances.2024013636.


Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects.

Newcomb R, Gao L, Vanderklish J, Tse A, Saylor M, Danielson C Transplant Cell Ther. 2024; 30(7):700-711.

PMID: 38685402 PMC: 11223964. DOI: 10.1016/j.jtct.2024.04.018.


International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Bone Marrow Transplant. 2024; 59(6):717-741.

PMID: 38413823 PMC: 11809468. DOI: 10.1038/s41409-023-02190-2.


International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Transplant Cell Ther. 2024; 30(4):349-385.

PMID: 38413247 PMC: 11181337. DOI: 10.1016/j.jtct.2023.12.001.


Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.

Tappeiner C, Heiligenhaus A, Halter J, Miserocchi E, Bandello F, Goldblum D Front Med (Lausanne). 2023; 10:1133381.

PMID: 36891189 PMC: 9987249. DOI: 10.3389/fmed.2023.1133381.


References
1.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

2.
Herzberg P, Heussner P, Mumm F, Horak M, Hilgendorf I, von Harsdorf S . Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16(12):1707-17. DOI: 10.1016/j.bbmt.2010.05.018. View

3.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J . Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143-238. PMC: 3103296. DOI: 10.1016/j.bbmt.2009.06.019. View

4.
Flowers M, Parker P, Johnston L, Matos A, Storer B, Bensinger W . Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002; 100(2):415-9. DOI: 10.1182/blood-2002-01-0011. View

5.
Williams K, Chien J, Gladwin M, Pavletic S . Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009; 302(3):306-14. PMC: 7357209. DOI: 10.1001/jama.2009.1018. View